MedPath

A prospective exploratory study on the safety of gastric endoscopic submucosal dissection without cessation of warfarin.

Phase 2
Conditions
The lesion that is indicated in gastric endoscopic submucosal dissection in patients who use warfarin for prevention of thrombosis.
Registration Number
JPRN-UMIN000020850
Lead Sponsor
The University of Tokyo Hospital Department of Gastroenterology, Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Women who has a possibility of pregnancy or is during pregnancy (2)Women who has baby and is nursing (3)Patients who undergo hemodialysis (4)To assess the general condition and complications of patients, if the attending physician has determined that it is difficult to entry.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The bleeding rate after gastric endoscopic submucosal dissection from immediately until the 28th day
Secondary Outcome Measures
NameTimeMethod
1.The existence of bleeding requiring hemostatic procedure in second-look gastrointestinal endoscopy (day1). 2.Early bleeding rate after gastric endoscopic submucosal dissection (from immediately after gastric endoscopic submucosal dissection to before the day2 meal starts). 3.Delayed bleeding rate after gastric endoscopic submucosal dissection (after the day2 meal started). 4.Duration of hospitalization.
© Copyright 2025. All Rights Reserved by MedPath